ATx has created groundbreaking drugs for dementia and Alzheimer’s. The Icelandic startup just raised €26mn to advance the ...

A series of disappointments that drove Sage Therapeutics Inc.’s stock down by 85% since August of 2023 has evolved into an unsolicited takeout offer by partner Biogen Inc., followed by a lawsuit filed ...

Alzheimer's disease is likely caused by stalled protein processing in the brain, according to a new study.

Eisai is seeking approval for an injectable version of Leqembi while Eli Lilly is developing a new injectable drug. These ...

The geroscience hypothesis focuses on extending the healthy lifespan by targeting aging mechanisms. Recent advances in ...

Research shows that GLP-1 receptor agonists like Ozempic can help you drop weight, manage diabetes, and even potentially ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

New research suggests that commonly used medications like antibiotics, antivirals, and anti-inflammatories could lower the ...

Billionaire investor Ken Griffin is the founder of Citadel Advisors, one of the world’s most successful alternative ...

Meanwhile, Sage reported failed phase 2 trials of dalzanemdor in Alzheimer's, Parkinson's, and Huntington's disease, and ...

Kyung Bo Kim discovered compounds that improved cognitive function regardless of amyloid plaque buildup — an encouraging sign ...

GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...